Combino Pharm: Memantine, a New Business Opportunity

Combino Pharm presents a new business opportunity with the product Memantine.

1. Product Description: memantine hydrochloride

2. Therapeutical indication: treatment of patients with moderate to severe Alzheimer’s disease.

3. Presentation: film-coated tablets of 10mg.

4. Highlights:

• FDF produced in our manufacturing facility in Malta
• DCP slot in DE available in May 2012

5. Patent status: European alzheimer use patent until 14/04/2014.

6. Regulatory details:

• API Supplier: EU
• DF: Combino Pharm Malta

7. Regulatory Strategy: dossier completed and submission in May 2012 as a national procedure in PT.